AzTrials
AzTrials

COPDREVISITSNCT05568043

The Reducing REVISITS Study: A Cluster RCT

A study testing COPD Transitions of Care Intervention Bundle: Virtual Interventions and COPD Transitions of Care Intervention Bundle: In-Person Interventions in people with COPD and COPD Exacerbation Acute, run by University of Chicago at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This type II hybrid effectiveness-implementation trial will concurrently study the comparative effectiveness of virtual vs. in-person COPD care transition programs implemented via virtual mentored implementation approaches with and without co-design methods. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
COPD, COPD Exacerbation Acute
What is being tested?
COPD Transitions of Care Intervention Bundle: Virtual Interventions and COPD Transitions of Care Intervention Bundle: In-Person Interventions
Could I receive a placebo?
No, everyone receives an active treatment
How many people
384 participants
Where
1 siteUnited States
Study dates
15 Feb 2022to 31 Mar 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Since enrollment for Aim 2 will occur on a site/system-level, the inclusion of specific individuals who meet these criteria are not applicable since Aim 2 will only enroll hospital sites, not individuals. The sites the investigators enroll will represent diverse patient populations and geographical locations across the US.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Chicago

    Chicago, Illinois, 60637

Other trials in United States

About this study

Official title: The Reducing Respiratory Emergency Visits Using Implementation Science Interventions Tailored to Setting (REVISITS) Study: A Cluster Randomized Trial

This type II hybrid effectiveness-implementation trial will concurrently study the comparative effectiveness of virtual vs. in-person COPD care transition programs implemented via virtual mentored implementation approaches with and without co-design methods.

The investigators will enroll up to 24 randomized sites (with a goal minimum of 16 sites) to:

Read more
  • Deliver the COPD programs implemented via mentored support in collaboration with SHM Center for Quality Improvement.
  • Compare the effectiveness and penetration of virtual versus in-person COPD care transition programs implemented along with mentoring support with or without co-design.

The investigators aim to determine which combined approach(es) is/are the most effective at implementing evidence-based COPD program interventions and decreasing COPD acute care revisits with the greatest overall impact and sustainability.

Read the detailed description

The COPD programs will be implemented via mentored support in collaboration with the SHM Center for Quality Improvement. Up to twenty-four hospitals will be randomized to one of four dyads: 1) in-person intervention delivery with virtual mentoring; 2) 1) in-person intervention delivery with virtual mentoring and co-design; 3) virtual intervention delivery with virtual mentoring; or 4) virtual intervention delivery with virtual mentoring with co-design. The research will use a pragmatic type II hybrid effectiveness-implementation cluster randomized trial such that once the hospital is randomized, the assigned program delivery (virtual vs. in-person) will be implemented via their assigned mentoring approach (virtual mentoring with/without co-desig) using quality improvement efforts. Each hospital will work with their mentors to implement their COPD care transition program (bundle of 2-3 interventions) based on their site-specific implementation plan developed in Aim 1 (already approved under this IRB number) according to their assigned delivery (in-person vs. virtual) over a one-year period; half of sites will also receive co-design support.

The mentored implementation model (MIM) is an evidence-based strategy to promote the success and sustainability of hospital-based quality improvement (QI) initiatives. After completing the contextual assessments and pre-implementation planning in Aim 1, the investigators will collaborate with the SHM to harness their expertise with the MIM to implement the COPD Program over a one-year period during Aim 2 (implementation). Virtual Mentored Implementation involves implementing their assigned care transition program intervention delivery method using an innovative virtual mentored implementation approach using tele-conferencing technology (i.e., video-conferences) for two-way visualization of individuals in different locations for educational purposes. In our proposal, the virtual site visits (≥1) and monthly mentoring sessions will use tele-conferencing so both the site-leads and mentor can visualize each other and the mentor can visualize and observe the site's additional team members, administrators, clinical and administrative space, data collection tools and technology, and any other resources and facilities that will allow the mentor to advise on optimal approaches for program implementation. Monthly mentoring sessions will occur using similar virtual teleconferencing technology to maximize mentors' input. Half of sites will also be randomized to co-design support with our study partner Onda Collective; the other half will only receive the virtual mentored support.

The sustainability of intervention and implementation outcomes will be evaluated at 6, 12, 18, and 24-months post-implementation. Mechanisms, moderators, and mediators will identify aspects of successful implementation, and program costs and savings will be analyzed across sites. These data will inform a dissemination strategy (e.g., toolkit) and will inform future large-scale implementation and cost-effectiveness studies. Site Leads will submit quarterly reports via REDCap and will be de-identified.

Qualitative contextual analyses across stakeholders (patients, clinicians, administrators) will assess for mediators, moderators, and mechanism of change using CFIR rating rules to determine valence (positive or negative influence on implementation and strength [influence on implementation weak or strong]). The investigators will use the CFIR matrix to compare within and across the up to 24 hospitals across each time point including baseline data collected in this context assessment, throughout relevant implementation time points, and post-implementation time points. To analyze the aggregate data, the investigators will use consensus-based coding: our team analysts will determine a summary rating using all of the individual, supporting qualitative, and rationale data into consideration and will discuss until the investigators reach consensus. Program costs/savings: The investigators will assess the value of implementation from the hospital's perspective, consistent with the study's focus on hospital-level implementation using implementation science economic evaluation principles to evaluate both the comparative program intervention and implementation costs. Principles of "cost of care" measures include actual costs (not billed costs), time-driven activity-based costing, and actual use of resources (actual time per patient, capacity cost, supporting costs), measured around the patient; implementation costs include: 1) startup costs: mentor training and education materials; 2) personnel costs (clinician/staff time); 3) supplies and space costs. The investigators will use monthly log sheets to collect the staff time and use self-administered tool to estimate startup costs. To calculate the costs of staff time, the investigators will determine an hourly wage on the basis of annual salaries and a 40-hour work week. All costs will be itemized and summarized annually with descriptive statistics including mean, SD, median, and interquartile range. To assess potential savings, value may be assessed differently depending on the sites' payment models. For instance, at sites that primarily or solely deliver care in fee-for-service payment models, reducing revisits may improve the quality of care, but not their financial bottom line, unless they significantly reduce their penalties under Medicare's HRRP. On the other hand, hospitals enrolled in value-based contracts, such as accountable care organizations and/or BPCI programs, may find that they are able to demonstrate improved savings or relative cost-savings by implementing programs. To determine overall value, the investigators will estimate site-specific 'savings' through estimated decreased Medicare penalties for excessive 30-day readmissions or by remaining under target for value-based purchasing contracts.

Being tested
COPD Transitions of Care Intervention Bundle: Virtual Interventions, COPD Transitions of Care Intervention Bundle: In-Person Interventions
Medical subject headings
Pulmonary Disease, Chronic Obstructive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • COPD Transitions of Care Intervention Bundle: Virtual InterventionsBehavioural

    Also called COPD Transitions of Care Program: Virtual Interventions

    The COPD Transitions of Care Intervention Bundle will be site-specific determined through Aim 1 contextual assessments and will consist of 2-3 evidence-based COPD transitions of care interventions. Virtual interventions included in the bundle may consist of: phone or e-consults for medication reconciliation, virtual teach-to-goal [V-TTG] or tele-TTG inhaler education, and post-discharge phone call communication and/or texts/ and/or electronic portal use, among others.

  • COPD Transitions of Care Intervention Bundle: In-Person InterventionsBehavioural

    Also called COPD Transitions of Care Program: In-Person Interventions

    The COPD Transitions of Care Intervention Bundle will be site-specific determined through Aim 1 contextual assessments and will consist of 2-3 evidence-based COPD transitions of care interventions. In-person interventions include face-to-face general COPD education, inhaler education, medication reconciliation, post-discharge clinic visits, community health worker home visits, pulmonary rehabilitation, smoking cessation programs, among others.

Study groups in NCT05568043
Study groupRoleWhat they receive
In-person intervention delivery with virtual mentoringExperimentalThe implemented interventions will be in-person and will include virtual mentoring. The mentored implementation model (MIM) is an evidence-based strategy to promote the success and sustainability of hospital-based quality improvement (QI) initiatives. After completing the contextual assessments and pre-implementation planning in Aim 1, the investigators will collaborate with the SHM to harness their expertise with the MIM to implement the COPD Program over a one-year period during Aim 2 (implementation). Virtual Mentored Implementation involves implementing their assigned care transition program intervention delivery method using an innovative virtual mentored implementation approach using tele-conferencing technology (i.e., video-conferences) for two-way visualization of individuals in different locations for educational purposes. Monthly mentoring sessions will occur to maximize mentors' input.
Receives: Behavioral: COPD Transitions of Care Intervention Bundle: In-Person Interventions
In-person intervention delivery with virtual mentoring and co-designExperimentalThe implemented interventions will be in-person and will include virtual mentoring and co-design support with our study partner, Onda Collective. The mentored implementation model (MIM) is an evidence-based strategy to promote the success and sustainability of hospital-based quality improvement (QI) initiatives. After completing the contextual assessments and pre-implementation planning in Aim 1, the investigators will collaborate with the SHM to harness their expertise with the MIM to implement the COPD Program over a one-year period during Aim 2 (implementation). Virtual Mentored Implementation involves implementing their assigned care transition program intervention delivery method using an innovative virtual mentored implementation approach using tele-conferencing technology (i.e., video-conferences) for two-way visualization of individuals in different locations for educational purposes. Monthly mentoring sessions will occur to maximize mentors' input.
Receives: Behavioral: COPD Transitions of Care Intervention Bundle: In-Person Interventions
Virtual intervention delivery with virtual mentoringExperimentalThe implemented interventions will be virtual and will include virtual mentoring. The mentored implementation model (MIM) is an evidence-based strategy to promote the success and sustainability of hospital-based quality improvement (QI) initiatives. After completing the contextual assessments and pre-implementation planning in Aim 1, the investigators will collaborate with the SHM to harness their expertise with the MIM to implement the COPD Program over a one-year period during Aim 2 (implementation). Virtual Mentored Implementation involves implementing their assigned care transition program intervention delivery method using an innovative virtual mentored implementation approach using tele-conferencing technology (i.e., video-conferences) for two-way visualization of individuals in different locations for educational purposes. Monthly mentoring sessions will occur to maximize mentors' input.
Receives: Behavioral: COPD Transitions of Care Intervention Bundle: Virtual Interventions
Virtual intervention delivery with virtual mentoring with co-designExperimentalThe implemented interventions will be virtual and will include virtual mentoring and co-design support with our study partner, Onda Collective. The mentored implementation model (MIM) is an evidence-based strategy to promote the success and sustainability of hospital-based quality improvement (QI) initiatives. After completing the contextual assessments and pre-implementation planning in Aim 1, the investigators will collaborate with the SHM to harness their expertise with the MIM to implement the COPD Program over a one-year period during Aim 2 (implementation). Virtual Mentored Implementation involves implementing their assigned care transition program intervention delivery method using an innovative virtual mentored implementation approach using tele-conferencing technology (i.e., video-conferences) for two-way visualization of individuals in different locations for educational purposes. Monthly mentoring sessions will occur to maximize mentors' input.
Receives: Behavioral: COPD Transitions of Care Intervention Bundle: Virtual Interventions

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Healthcare Utilization: 30-day acute care revisits for COPD

    Composite of all emergency department visits and/or re-hospitalizations within 30-days post index hospitalization across all enrolled sites for COPD

    Measured: Immediately Post-Program Implementation (12 months after enrollment in Aim 2)

  2. Delivery of overall care transition program: penetration

    Proportion of hospitalized patients with COPD receiving their assigned care transition program interventions (composite) as per documented in the electronic health record.

    Measured: Immediately Post-Intervention (12 months after enrollment in Aim 2)

  3. Sustainability of effectiveness: 30-day revisits

    Composite of all emergency department visits and/or re-hospitalizations within 30-days post index hospitalization.

    Measured: Quarterly for 24 months Post-Intervention initial enrollment (Aim 3)

  4. Sustainability of program delivery: penetration

    Proportion of hospitalized patients with COPD receiving their assigned care transition program interventions (composite) as per documented in the electronic health record.

    Measured: Quarterly for 24 months Post-Intervention initial enrollment (Aim 3)

Secondary outcomes (39)
  1. Delivery of care transition program individual interventions: penetration

    Proportion of patients with documented individual care transition interventions including: on admission and/or upon discharge medication reconciliation [yes/no]; self-management education, e.g., inhaler technique including baseline and/or post-education technique documentation [scores/descriptive] and/or whether education was provided [yes/no]; documentation that post-discharge communication occurred (Y/N); other site-specific care transition interventions (site-specific).

    Measured: Immediately Post-Intervention (12 months after enrollment in Aim 2)

  2. Cost/savings evaluation

    To evaluate hospital-level program costs and savings.

    Measured: At completion of 12- months of Intervention (Aim 3)

  3. Cost/savings evaluation

    To evaluate hospital-level program costs and savings.

    Measured: At 24 months Post-Intervention (Aim 3)

  4. Healthcare Utilization: 30-day acute care revisits for COPD during intervention

    Composite of all emergency department visits and/or re-hospitalizations within 30-days for COPD post index hospitalization across all enrolled sites.

    Measured: Immediately Post-Program Implementation (12 months after enrollment in Aim 2)

  5. Healthcare Utilization: 30-day acute care revisits for COPD

    Composite of all emergency department visits and/or re-hospitalizations within 30-days for COPD post index hospitalization across all enrolled sites.

    Measured: Post-Program Implementation (24 months after enrollment in Aim 3)

  6. Healthcare Utilization: 60-day acute care revisits for COPD

    Composite of all emergency department visits and/or re-hospitalizations within 60-days for COPD post index hospitalization across all enrolled sites.

    Measured: Immediately Post-Program Implementation (12 months after enrollment in Aim 2)

  7. Healthcare Utilization: 60-day acute care revisits for COPD

    Composite of all emergency department visits and/or re-hospitalizations within 60-days for COPD post index hospitalization across all enrolled sites.

    Measured: Post-Program Implementation (24 months after enrollment in Aim 3)

  8. Healthcare Utilization: 90-day acute care revisits for COPD

    Composite of all emergency department visits and/or re-hospitalizations within 90-days for COPD post index hospitalization across all enrolled sites.

    Measured: Immediately Post-Program Implementation (12 months after enrollment in Aim 2)

  9. Healthcare Utilization: 90-day acute care revisits for COPD

    Composite of all emergency department visits and/or re-hospitalizations within 90-days for COPD post index hospitalization across all enrolled sites.

    Measured: Post-Program Implementation (24 months after enrollment in Aim 3)

  10. Healthcare Utilization: 30-day acute care revisits (all cause)

    Composite of all emergency department visits and/or re-hospitalizations within 30-days post index hospitalization across all enrolled sites.

    Measured: Immediately Post-Program Implementation (12 months after enrollment in Aim 2)

  11. Healthcare Utilization: 30-day acute care revisits (all cause)

    Composite of all emergency department visits and/or re-hospitalizations within 30-days post index hospitalization across all enrolled sites.

    Measured: Post-Program Implementation (24 months after enrollment in Aim 3)

  12. Healthcare Utilization: 60-day acute care revisits (all cause)

    Composite of all emergency department visits and/or re-hospitalizations within 60-days post index hospitalization across all enrolled sites.

    Measured: Immediately Post-Program Implementation (12 months after enrollment in Aim 2)

  13. Healthcare Utilization: 60-day acute care revisits (all cause)

    Composite of all emergency department visits and/or re-hospitalizations within 60-days post index hospitalization across all enrolled sites.

    Measured: Post-Program Implementation (24 months after enrollment in Aim 3)

  14. Healthcare Utilization: 90-day acute care revisits (all cause)

    Composite of all emergency department visits and/or re-hospitalizations within 90-days post index hospitalization across all enrolled sites.

    Measured: Immediately Post-Program Implementation (12 months after enrollment in Aim 2)

  15. Healthcare Utilization: 90-day acute care revisits (all cause)

    Composite of all emergency department visits and/or re-hospitalizations within 90-days post index hospitalization across all enrolled sites.

    Measured: Post-Program Implementation (24 months after enrollment in Aim 3)

  16. Healthcare Utilization: 30-day emergency department revisits for COPD

    All emergency department visits within 30-days post index hospitalization for COPD across all enrolled sites.

    Measured: Immediately Post-Program Implementation (12 months after enrollment in Aim 2)

  17. Healthcare Utilization: 30-day emergency department revisits for COPD

    All emergency department visits within 30-days post index hospitalization for COPD across all enrolled sites.

    Measured: Post-Program Implementation (24 months after enrollment in Aim 3)

  18. Healthcare Utilization: 60-day emergency department revisits for COPD

    All emergency department visits within 60-days post index hospitalization for COPD across all enrolled sites.

    Measured: Immediately Post-Program Implementation (12 months after enrollment in Aim 2)

  19. Healthcare Utilization: 60-day emergency department revisits for COPD

    All emergency department visits within 60-days post index hospitalization for COPD across all enrolled sites.

    Measured: Post-Program Implementation (24 months after enrollment in Aim 3)

  20. Healthcare Utilization: 90-day emergency department revisits for COPD

    All emergency department visits within 90-days post index hospitalization for COPD across all enrolled sites.

    Measured: Immediately Post-Program Implementation (12 months after enrollment in Aim 2)

  21. Healthcare Utilization: 90-day emergency department revisits for COPD

    All emergency department visits within 90-days post index hospitalization for COPD across all enrolled sites.

    Measured: Post-Program Implementation (24 months after enrollment in Aim 3)

  22. Healthcare Utilization: 30-day emergency department revisits (all cause)

    All emergency department visits within 30-days post index hospitalization across all enrolled sites.

    Measured: Immediately Post-Program Implementation (12 months after enrollment in Aim 2)

  23. Healthcare Utilization: 30-day emergency department revisits (all cause)

    All emergency department visits within 30-days post index hospitalization across all enrolled sites.

    Measured: Post-Program Implementation (24 months after enrollment in Aim 3)

  24. Healthcare Utilization: 60-day emergency department revisits (all cause)

    All emergency department visits within 60-days post index hospitalization across all enrolled sites.

    Measured: Immediately Post-Program Implementation (12 months after enrollment in Aim 2)

  25. Healthcare Utilization: 60-day emergency department revisits (all cause)

    All emergency department visits within 60-days post index hospitalization across all enrolled sites.

    Measured: Post-Program Implementation (24 months after enrollment in Aim 3)

  26. Healthcare Utilization: 90-day emergency department revisits (all cause)

    All emergency department visits within 90-days post index hospitalization across all enrolled sites.

    Measured: Immediately Post-Program Implementation (12 months after enrollment in Aim 2)

  27. Healthcare Utilization: 90-day emergency department revisits (all cause)

    All emergency department visits within 90-days post index hospitalization across all enrolled sites.

    Measured: Post-Program Implementation (24 months after enrollment in Aim 3)

  28. Healthcare Utilization: 30-day re-hospitalizations for COPD

    All re-hospitalizations within 30-days post index hospitalization for COPD across all enrolled sites.

    Measured: Immediately Post-Program Implementation (12 months after enrollment in Aim 2)

  29. Healthcare Utilization: 30-day re-hospitalizations for COPD

    All re-hospitalizations within 30-days post index hospitalization for COPD across all enrolled sites.

    Measured: Post-Program Implementation (24 months after enrollment in Aim 3)

  30. Healthcare Utilization: 60-day re-hospitalizations for COPD

    All re-hospitalizations within 60-days post index hospitalization for COPD across all enrolled sites.

    Measured: Immediately Post-Program Implementation (12 months after enrollment in Aim 2)

  31. Healthcare Utilization: 60-day re-hospitalizations for COPD

    All re-hospitalizations within 60-days post index hospitalization for COPD across all enrolled sites.

    Measured: Post-Program Implementation (24 months after enrollment in Aim 3)

  32. Healthcare Utilization: 90-day re-hospitalizations for COPD

    All re-hospitalizations within 90-days post index hospitalization for COPD across all enrolled sites.

    Measured: Immediately Post-Program Implementation (12 months after enrollment in Aim 2)

  33. Healthcare Utilization: 90-day re-hospitalizations for COPD

    All re-hospitalizations within 90-days post index hospitalization for COPD across all enrolled sites.

    Measured: Post-Program Implementation (24 months after enrollment in Aim 3)

  34. Healthcare Utilization: 30-day re-hospitalizations (all cause)

    All re-hospitalizations within 30-days post index hospitalization across all enrolled sites.

    Measured: Immediately Post-Program Implementation (12 months after enrollment in Aim 2)

  35. Healthcare Utilization: 30-day re-hospitalizations (all cause)

    All re-hospitalizations within 30-days post index hospitalization across all enrolled sites.

    Measured: Post-Program Implementation (24 months after enrollment in Aim 3)

  36. Healthcare Utilization: 60-day re-hospitalizations (all cause)

    All re-hospitalizations within 60-days post index hospitalization across all enrolled sites.

    Measured: Immediately Post-Program Implementation (12 months after enrollment in Aim 2)

  37. Healthcare Utilization: 60-day re-hospitalizations (all cause)

    All re-hospitalizations within 60-days post index hospitalization across all enrolled sites.

    Measured: Post-Program Implementation (24 months after enrollment in Aim 3)

  38. Healthcare Utilization: 90-day re-hospitalizations (all cause)

    All re-hospitalizations within 90-days post index hospitalization across all enrolled sites.

    Measured: Immediately Post-Program Implementation (12 months after enrollment in Aim 2)

  39. Healthcare Utilization: 90-day re-hospitalizations (all cause)

    All re-hospitalizations within 90-days post index hospitalization across all enrolled sites.

    Measured: Post-Program Implementation (24 months after enrollment in Aim 3)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Oct 2022
  2. Study start15 Feb 2022
  3. Primary completion31 Mar 2024
  4. Study completion31 Mar 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Factorial
Model description
2x2 with 2 intervention delivery methods (virtual vs. in-person) and 2 implementation support mechanisms (virtual mentoring vs. virtual mentoring plus co-design)
Masking
None (open label)
Enrolment
384 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05568043
Sponsor's protocol ID
20-0373
Other IDs
5R01HL146644-05
Acronym
REVISITS
Status last verified
Jul 2026
First submitted
14 Jul 2022
Last updated
7 Jul 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Akula M, Erwin K, Traeger L, Pick H, Gao F, Damschroder L, Press VG. Contextual Assessments for Chronic Obstructive Pulmonary Disease Transition of Care Bundle Implementation Planning for the Reduce REVISITS Study: Rapid Sequential Explanatory Mixed Methods Approach. JMIR Hum Factors. 2026 Mar 2;13:e82078. doi: 10.2196/82078.

    PubMed 41773688
  • Lee CT, Traeger L, Akula M, Fegley AE, Goldstein J, Erwin K, Damschroder LJ, Rommes J, Pick H, Auerbach A, Lindenauer P, Wan W, Jackson Sagredo A, Press VG. Virtual Mentored Implementation to Improve Care Transitions in Chronic Obstructive Pulmonary Disease: Protocol for a Pragmatic Implementation Study. JMIR Res Protoc. 2026 Jan 13;15:e82043. doi: 10.2196/82043.

    PubMed 41529255

Questions about this trial

What is this clinical trial studying?

A study testing COPD Transitions of Care Intervention Bundle: Virtual Interventions and COPD Transitions of Care Intervention Bundle: In-Person Interventions in people with COPD and COPD Exacerbation Acute, run by University of Chicago at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Healthcare Utilization: 30-day acute care revisits for COPD (time frame: Immediately Post-Program Implementation (12 months after enrollment in Aim 2)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05568043, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jul 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in